Vita Therapeutics

NEW CLINICAL TRIALS MADE POSSIBLE BY CGMP MIXED-USE FACILITY

Founded by industry pioneers including Dr. Doug Ethell and Robert M. Laverty, Vita Therapeutics is a cell engineering company harnessing the power of genetics to develop cellular treatment for muscular dystrophy and solid tumors. The company uses induced pluripotent stem cell technology to engineer specific cell types to replace defective cells. Moving the mission forward are top-notch facilities and equipment as well as skilled researchers and clinicians. The challenge: To expand the company’s Maryland presence. The solution: A new Current Good Manufacturing Practices (cGMP) mixed-use facility developed by VaLogic.

Breakthrough therapies supporting Vita’s aim for global leadership.

Experienced in the creation of cGMP-compliant facilities, VaLogic brought real-world knowledge to the project, expediting and enhancing the design process for a facility that will feature three cleanroom suites with a robust program of cGMP-supported laboratory spaces. This new facility is allowing the company to conduct early-to-mid stage clinical trials for several of its leading therapy candidates. These trials support the company’s aim to be a global leader with a robust pipeline of programs.